Leaders in Pharmaceutical Business Intelligence (LPBI) Group

2:25 pm – 3:15 pm 3/26/2015 Better Business Track: Externalizing Pharma R&D @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015

Reporter: Aviva Lev-Ari, PhD, RN

Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM

Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media

http://pharmaceuticalintelligence.com

Panelists:

• Ashish Dugar, Head, External Development Group, Roche

Building the pipeline by resources: Roche NY, Washington DC,

Same company many have centers that capacity constrained other are Capital constrains, some may have both

Partnership can challenge internal bias, critique by a partner is fruitful and productive

Large pipeline is good

ARC – Academic Research Collaborations is very active

• Thomas Luby, Senior Director of New Ventures , Johnson & Johnson Innovation

Cambridge is the hub for talent, who does what and influence collaboration, a venture in a Biotech Center

Internalization comes first then externalization

Capacity to invest at difference Capital cycles

MA becomes Pharma like but Biotech spirit will continue to drive

Oncology needs a payment revolution to be viable as healthcare costs

• John Orloff, ‎Global Head of Research and Development, Baxter BioSciences

Office in Cambridge and Vienna

Partnership can lead to lost of control

Partnership on Clinical Operation for externalization

• Jonathan Gertler

Transition from Academia, start ups,

Corporate commitment is very importance, small companies are more vulnerable than larger

Drivers for success: IP, best resources are not integrate-able, thus externalization will persist

Academic Freedom can be impacted by Collaboration

Moderator:

• Tacye Connolly, Owner, RRG, A VCLS Company